Cargando…
Cutaneous reactions caused by nitrofurazone
INTRODUCTION: Allergic contact dermatitis (ACD) is a form of dermatitis due to type 4 hypersensitivity reaction that occurs when the skin comes into contacts with the topical product. Topical nitrofurazone is a widely used antimicrobial drug in our country which is well known to cause ACD. AIM: In t...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791145/ https://www.ncbi.nlm.nih.gov/pubmed/31616212 http://dx.doi.org/10.5114/ada.2019.87444 |
_version_ | 1783458924951764992 |
---|---|
author | Bilgili, Serap Gunes Ozaydin-Yavuz, Goknur Yavuz, Ibrahim Halil Bilgili, Mehmet Ali Karadag, Ayse Serap |
author_facet | Bilgili, Serap Gunes Ozaydin-Yavuz, Goknur Yavuz, Ibrahim Halil Bilgili, Mehmet Ali Karadag, Ayse Serap |
author_sort | Bilgili, Serap Gunes |
collection | PubMed |
description | INTRODUCTION: Allergic contact dermatitis (ACD) is a form of dermatitis due to type 4 hypersensitivity reaction that occurs when the skin comes into contacts with the topical product. Topical nitrofurazone is a widely used antimicrobial drug in our country which is well known to cause ACD. AIM: In this study, ACD cases with different clinical features attributed to the use of nitrofurazone were evaluated. MATERIAL AND METHODS: Patients hospitalized in our clinic between 2013 and 2017 with ACD diagnosis due to nitrofurazone were evaluated. The patient age, gender, atopy histories, clinical features, dissemination of the lesions, treatment given were reviewed. RESULTS: In a 5-year period, 58 cases were identified and their data were analysed. Twelve patients were female (21%), 46 patients were male (79%). Clinical presentations were dyshidrosiform (45%), excoriated papules and plaques (33%), combined (21%), and erythroderma in one patient. The dissemination was generalized in 34 patients, localized in 14 patients, and local spread in 10 patients. The mean hospitalization time was 7 ±3 days, and ranged from 3 to 18 days. CONCLUSIONS: There may be widespread and severe ACD due to the use of nitrofurazone. Topical nitrofurazone should not be applied on damaged skin as sensitization may develop. Patients and physicians should be aware of the ACD risk associated with topical nitrofurazone, which is also commonly used as self-medication, physicians should take a detailed history of the drug use and products containing nitrofurazone should not be used in conditions where skin integrity is not intact, whenever possible. |
format | Online Article Text |
id | pubmed-6791145 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-67911452019-10-15 Cutaneous reactions caused by nitrofurazone Bilgili, Serap Gunes Ozaydin-Yavuz, Goknur Yavuz, Ibrahim Halil Bilgili, Mehmet Ali Karadag, Ayse Serap Postepy Dermatol Alergol Original Paper INTRODUCTION: Allergic contact dermatitis (ACD) is a form of dermatitis due to type 4 hypersensitivity reaction that occurs when the skin comes into contacts with the topical product. Topical nitrofurazone is a widely used antimicrobial drug in our country which is well known to cause ACD. AIM: In this study, ACD cases with different clinical features attributed to the use of nitrofurazone were evaluated. MATERIAL AND METHODS: Patients hospitalized in our clinic between 2013 and 2017 with ACD diagnosis due to nitrofurazone were evaluated. The patient age, gender, atopy histories, clinical features, dissemination of the lesions, treatment given were reviewed. RESULTS: In a 5-year period, 58 cases were identified and their data were analysed. Twelve patients were female (21%), 46 patients were male (79%). Clinical presentations were dyshidrosiform (45%), excoriated papules and plaques (33%), combined (21%), and erythroderma in one patient. The dissemination was generalized in 34 patients, localized in 14 patients, and local spread in 10 patients. The mean hospitalization time was 7 ±3 days, and ranged from 3 to 18 days. CONCLUSIONS: There may be widespread and severe ACD due to the use of nitrofurazone. Topical nitrofurazone should not be applied on damaged skin as sensitization may develop. Patients and physicians should be aware of the ACD risk associated with topical nitrofurazone, which is also commonly used as self-medication, physicians should take a detailed history of the drug use and products containing nitrofurazone should not be used in conditions where skin integrity is not intact, whenever possible. Termedia Publishing House 2019-08-30 2019-08 /pmc/articles/PMC6791145/ /pubmed/31616212 http://dx.doi.org/10.5114/ada.2019.87444 Text en Copyright: © 2019 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Original Paper Bilgili, Serap Gunes Ozaydin-Yavuz, Goknur Yavuz, Ibrahim Halil Bilgili, Mehmet Ali Karadag, Ayse Serap Cutaneous reactions caused by nitrofurazone |
title | Cutaneous reactions caused by nitrofurazone |
title_full | Cutaneous reactions caused by nitrofurazone |
title_fullStr | Cutaneous reactions caused by nitrofurazone |
title_full_unstemmed | Cutaneous reactions caused by nitrofurazone |
title_short | Cutaneous reactions caused by nitrofurazone |
title_sort | cutaneous reactions caused by nitrofurazone |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791145/ https://www.ncbi.nlm.nih.gov/pubmed/31616212 http://dx.doi.org/10.5114/ada.2019.87444 |
work_keys_str_mv | AT bilgiliserapgunes cutaneousreactionscausedbynitrofurazone AT ozaydinyavuzgoknur cutaneousreactionscausedbynitrofurazone AT yavuzibrahimhalil cutaneousreactionscausedbynitrofurazone AT bilgilimehmetali cutaneousreactionscausedbynitrofurazone AT karadagayseserap cutaneousreactionscausedbynitrofurazone |